3-Methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine → 2-(5-Methoxypyridin-3-yl)-4-morpholino-6-((4-n-methylsulfonylpiperazin-1-yl)methyl)thieno[3,2-d]pyrimidine

참여 물질

역할	이름	HCID	투입량
반응물	3-Methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine	HCID 3866161	—
반응물	4-(2-Chloro-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine	HCID 23650837	—
생성물	2-(5-Methoxypyridin-3-yl)-4-morpholino-6-((4-n-methylsulfonylpiperazin-1-yl)methyl)thieno[3,2-d]pyrimidine	HCID 58234051	—

반응 단계

2-Chloro-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine, prepared via General Procedure B-3, was reacted with 3-methoxypyridine-5-boronic acid pinacol ester in General Procedure A. Purification on silica and ether trituration gave 243. NMR (CDCl3): 2.68-2.72 (4H, m), 2.82 (3H, s), 3.29-3.33 (4H, m), 3.90 (2H, s), 3.90-3.94 (4H, m), 4.00 (3H, s), 4.05-4.10 (4H, m), 7.35 (1H, s), 8.23 (1H, s), 8.38 (1H, s), 9.26 (1H, s). MS (ESI+): MH+505.19 (100%)

출처 및 근거

DOI	10.6084/m9.figshare.5104873.v1
특허 번호	US07888352B2
출처 데이터셋	uspto-grants-2011_02
ORD ID	ord-327d1618dd7b497aa0e348e8a5d51398
출처 메모	uspto-grants-2011_02